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1. Introduction 
IVF has been widely used since 1978 (Steptoe & Edwards, 1978) to help infertile couples 
conceive when nature has failed. The IVF field was improved through embryo 
freezing/thawing, a technique developed by A. Trounson (Trounson & Mohr, 1983). The 
next major innovation came with ICSI in 1992, through the work of G.P. Palermo (Palermo 
et al., 1992). C. Chen was the first to publish work on oocyte freezing (Chen, 1986), but 
results remained too unreliable for this technique to be adopted in routine ART practice. 
Oocyte freezing became the focus of experimental efforts when in 1999 the first birth using 
oocyte vitrification was reported by L. Kuleshova (Kuleshova et al., 1999). M. Kuwayama in 
a 2005 publication confirmed that this new procedure could be useful in clinical practice 
(Kuwayama et al., 2005). Within a few years his method for freezing the human oocyte has 
become the standard for the field. Its clinical application has been widely developed and is 
now routine, even if other variants have since been proposed. There have been efforts to 
assess the safety of the procedure (Chian et al., 2008, Noyes et al., 2009). Noteworthy is R. 
Chian’s report on the health of 200 babies born after having been conceived with vitrified 
oocytes. The safety of the procedure is also supported by all the data available on the health 
of children born from vitrified embryos (Takahashi et al., 2005, Mukaida et al., 2009). Use of 
the technique has reached France (Boyer et al., 2010) with passage of a new bioethics law in 
the summer of 2011. From Italy we have a good overview of what takes place on a nation-
wide basis once the technique has become standard practice, thanks to the yearly report of 
ART results published by the country's ministry of health (Relazione del Ministro della 
Salute, anno 2009).  
Some issues are still being debated, e.g. an open versus closed system, infectious risks with 
Liquid Nitrogen (LN), the safety of cryoprotectants, the health of the unborn children. It is 
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known that for oocyte vitrification to be most successful an open system is still needed, as 
shown recently by Paffoni and colleagues (Paffoni et al., 2011). The major concern with 
regard to an open system is the risk of LN-mediated transmission of infective agents. 
Researchers testing the safety of the closed system have shown it is possible to introduce 
contaminants voluntarily into a LN environment. They have suggested taking certain 
precautions when using an open system. To safeguard samples in the storage container, 
they recommend sealing the samples after cooling and prior to storage (Bielanski & Vajta, 
2009). Parmegiani and colleagues (Parmegiani et al., 2010) suggest sterilizating LN by UV 
light. However, though safe and easy, UV sterilization is a costly procedure. The debate 
over the health of children born through oocyte vitrification is one that will not be resolved 
overnight. However, all the evidence published so far is reassuring. We should remember 
that when IVF, embryo freezing/thawing and ICSI were first developed, each advance was 
faced with similar resistance. What has changed is the success of national health authorities 
in imposing “precaution as a rule" as the only politically correct point of view. Most forget 
they would have probably banished IVF or ICSI back in the old days. Fortunately, 
international collaborations have produced quality studies which demonstrate that this new 
method is almost as safe as the slow-freezing method (Gook & Edgar, 2007, 2009, Cutting et 
al., 2009; Dessolle et al., 2009; Fadini et al., 2009, Nagy et al., 2009; Smith et al., 2010, 
Parmegiani et al., 2011). Good results for zygotes (Al-Hasani et al., 2007), day-2 or 3 embryos 
(Balaban et al., 2008) and embryos in blastocyst phase (Mukaida et al., 2009) have been 
obtained. The superiority to slow-freezing and the adaptability of fast-freezing to a closed 
system have also been demonstrated for embryos (VanderZwalmen et al., 2007) but these 
improvements will have fewer consequences for the future of ART than egg freezing. The 
new technique will probably render obsolete the cumbersome programmable freezers (Vajta 
& Nagy, 2009), but that is a mere detail compared to the other gains that can be expected. At 
this juncture, we must remember our debt to R. Edwards. We continue to be guided by both 
his brilliant work and his fearlessness and combativity in the cause of innovation, which led 
to international recognition and eventually the Nobel Prize. The message is clear:  we must 
carry on his footsteps. 
Cryobiology has developed steadily over several decades and along with ICSI has provided 
the conditions for a new clinical approach to ART practice. We are now ready to adopt 
oocyte vitrification in our biological and clinical procedures. The changes will lead to a more 
efficient and probably more humane practice.  
2. Vitrification: Its importance in IVF  
2.1 Increasing the number of fresh embryo transfers 
The new approach allows cryopreservation of a part of the oocyte cohort, rather than 
creating embryos and then freezing any unused ones. Until now, because of the very short 
lifetime of this particular cell, the procedure required that we fertilize all mature oocytes, 
verify fertilization, discard all unfertilized oocytes and freeze the non-transferred fertilized 
eggs (often called supernumeraries or additional embryos) for subsequent attempts. This 
procedure results in only one fresh embryo transfer, often undertaken in less than optimal 
conditions because of the ovarian status of hyper stimulation. The frozen embryos may 
serve in subsequent attempts, programmed close to the initial attempt in the case of 
implantation failure, or after parturition. In some cases, the frozen embryos are not reused 
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because the couple has decided against transfer (they may feel they do not want any more 
children, or divorce or death may have intervened in the meantime). Currently, many frozen 
embryos are being conserved simply because the couple is undecided whether to proceed 
with another transfer or most often cannot face the decision to destroy them. In France, the 
couple legally has three alternatives: end the cryo-conservation of their embryos, allow early 
adoption by another couple facing a double sterility, or donate their embryos to research. 
(Paradoxically the law also forbids research on embryos conceived for that purpose.)  
In Italy, a 2004 law (Legge N40) forbidding cryopreservation of the embryo forced  
resumption of work on oocyte freezing, with some encouraging results published by E. 
Porcu (Porcu et al., 1997). But even with modified slow-freezing in association with ICSI, 
results were not sufficient for the rest of Europe to follow suit. It was only after the 
publication of work by M. Kuwayama that IVF centres realized that oocyte freezing could be 
used in their practice. With rapid improvements in open system freezing, A. Cobo published 
results from a donor program showing that vitrified oocytes were equal in quality to fresh 
oocytes (Cobo et al., 2008, 2009). Because of their 2004 law, Italian teams realized that their 
situation was ideal to evaluate the efficiency of vitrification in an IVF program 
(Chamayou et al., 2006). Two major publications demonstrate the validity of the new 
procedure (Rienzi et al., 2010; Ubaldi et al., 2010). The embryo obtained with a 
vitrified/rewarmed oocyte has the same implantation rate as a fresh one demonstrated by 
L. Rienzi (Rienzi et al., 2010). Her report in Human Reproduction was the publication's 
most frequently downloaded work of the year 2011. A few months later F. Ubaldi from 
the same Roman team demonstrated that cumulative rates of pregnancy from the same 
cohort are equivalent to the cumulative rates from repeated attempts (Ubaldi et al., 2010). 
These publications underline the quality of the embryo produced from vitrification and its 
ability to implant. Oocyte vitrification will soon be widely adopted in IVF centres, as 
suggested in a recent meta-analysis review (Cobo & Diaz 2011). Each laboratory can 
decide to propose egg vitrification as an alternative to embryo freezing. In most centres 
employing micromanipulation, the technique itself is easily learned but its introduction in 
IVF programs requires some thought. Each centre will need to adopt its own strategy. In 
our centre we plan to conduct a study in which couples will be asked whether they prefer 
embryo or egg freezing, thus respecting their choice in the matter. It is expected some 
patients will still prefer to freeze their embryos, though once informed of the poorer 
implantation rates, they may decide to choose egg vitrification. (Currently in France, out 
of 100 births, 85 result from fresh transfer compared to 15 from thawing cycles.)  We may 
of course modify our approach when comparative results for transfer of embryos 
produced from vitrified eggs are available on a large scale. Our study, to be conducted on 
the first couples for whom egg vitrification will be available in our centre (Boyer et al., 
2009) is complementary to that of L. Rienzi (Rienzi et al., 2010). The benefit will be 
evaluated in terms of the probability of transfer for one selected oocyte. In a recent brief 
survey at our centre, half of the couples questioned said they would prefer oocyte 
freezing. We expect this proportion will increase when oocyte freezing becomes a real 
option.  
In France, because the law prohibits research on human embryos produced for that purpose, 
research is conducted with embryos which for whatever reason have been rejected for 
human reproduction. This needs to be made clear to prospective parents (and to lawmakers 
as well).  
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2.1.1 The risk/reward balance of ovarian stimulation 
Ovarian stimulation can proceed as usual; there will be no changes to the first step of IVF. 
We learn from the Italian experience that only 50% of the oocytes are of good quality, that is 
to say, appropriate for ICSI or vitrification. The first examination of the oocytes is crucial for 
a good result. An attempt at transfer will take place and the selected unused eggs will be 
vitrified for delayed microinjection. Egg banking schedules must take into account the 
number of couples who choose embryo freezing and also the number of embryos to be 
produced and transferred, as determined in our discussions with the couple. For transfers of 
embryos produced from vitrified oocytes, appointments will be based on the patient's 
menstrual cycle. In scheduling here we must be careful not to overload laboratory capacity.  
An oocyte thawing cycle will be planned if the patient is not pregnant from the first transfer. 
Thawing of oocytes will be done 2 days after the LH surge or after triggering with hCG. All 
the cycles used for transfer will be free from ovarian stimulation risk. The natural cycle is 
preferred as it is the most favourable for embryo implantation.  
The true challenge for centres offering an oocyte vitrification option will be scheduling the 
interventions. Clinicians must have a voice in the process. The laboratory calendar will have 
to take into account both fresh transfer and thawing cycles. If the natural cycle is most 
favourable for implantation, as has been reported, we will have to ensure that the laboratory 
can cope. The best day for the patient may not always be possible for the biologist! 
2.1.2 Managing the oocyte cohort after pick-up 
Centres must master the new procedure as developed by the leaders in the field, but for 
experienced biologists with skill in micromanipulation, the learning curve is not particularly 
steep. Within a very short time our centre was able to obtain oocytes or embryos of as good 
a quality as before vitrification and which, when transferred, resulted in ongoing 
pregnancies. (Fig 1, 2 and 3) 
 
Fig. 1. Oocyte dehydration. In (A) the oocyte before dehydration begins. (B-D) the oocyte during 
dehydration: shrinkage. (E) the oocyte regaining original form with cryoprotectant filling. 
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Fig. 2. Oocyte thawing and ICSI. (A-C) Oocyte shrinkage and re-gaining form during 
thawing. (D) Oocyte post-thawing. (E) Sperm selection for ICSI. (F) Oocyte post-ICSI. 
 
 
 
 
 
Fig. 3. Fresh oocyte development after vitrification, thawing and ICSI, identical to fresh 
oocytes development. (A) Zygote, day 1 in culture. (B) 4-cell embryo, day 2. (C) 8-cell 
embryo, day 3. (D) Morula, day 4. (E) Blastocyst, day 5. 
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The difficulty today remains deciding how many oocytes should be fertilized and how 
many vitrified. The daily practice of Italian teams and the results published in their annual 
report indicate that some 50% of the recovered oocytes are of good quality -- mature, in 
metaphase II, fertilizable and freezable. Based on their experience, it would be probably 
reasonable to propose 3 to 6 oocytes for fertilization, and vitrification of the rest. We can 
adjust these figures after some years of experience, as we did with ICSI. The number can be 
decided with each couple before starting the procedure. As a result we should be able to 
limit significantly the number of embryos produced as well as the number of frozen oocytes, 
without eliminating embryo freezing altogether. 
After the denudation step, ICSI can be performed on part of the cohort as usual, followed by 
a fresh embryo transfer. The single embryo transfer is more frequent nowadays and the 
over-production of embryos is no longer necessary. The second portion of mature oocytes 
from the cohort can be vitrified for each patient. They will be used in a future attempt if the 
first embryo transfer has failed.  
2.1.3 Overseeing the thawing of vitrified oocytes  
As with single ovarian stimulation, most patients have more oocytes than they need for an 
embryo transfer. In more than half of all IVF cycles, there will be spare oocytes for at least 
one other fresh transfer, this time from the vitrified oocyte. For the second fresh transfer, the 
thawing of the selected oocytes must be scheduled early in the morning to allow for at least 
2 hours in the incubator before fertilization. ICSI will be performed in all the surviving 
oocytes, with more than a 90 percent survival rate expected. Embryos are obtained and the 
transfer is organized as usual.  
2.2 Impact on egg donation 
Oocyte vitrification will have a major impact on egg donation by eliminating the complex 
coordination of donors and recipients. The need for synchronization between donor and 
recipient teams vanishes, simplifying all the steps necessary in preparing the donation. The 
creation of frozen egg banks will free us from the restraints which had previously limited 
our activity. Throughout the world, the mis-match between supply and demand has 
generated a lucrative business in which some of us have unfortunately become involved. 
Originally in almost all countries egg donation was developed for the altruistic purpose of 
providing healthy eggs to young women who for various reasons -- genetic, immunological, 
viral, and iatrogenic—were unable to produce them on their own. But in practice much of 
the demand has come from women who have turned to ART because of their age. Egg 
vitrification has opened the door to a new type of demand. A woman under 30 may now 
choose to preserve her fertility, even if she has no husband or plan for children at the time. 
Whether this possibility is a good thing is still matter of debate. However, we may 
legitimately ask if it is not better for a woman to preserve her own eggs at the age of 25 than 
to travel to a foreign country at the age of 45 to buy the eggs of young women there. 
Undoubtedly, we need to reflect on the implications of what has been termed “social egg 
freezing” (Lockwood, 2011). It is probably best to seek the answer from young women 
themselves rather than from bioethics committees whose members are often close to 
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retirement. It is instructive in this regard to be in contact with teenage girls. We have often 
been surprised by their level of comfort with ART compared to older generations. The high 
cost of the new procedure poses problems of another order. With the advent of oocyte 
vitrification, the entire issue of egg donation will have to be re-evaluated, just as sperm 
donation had to be rethought when ICSI was first introduced.  
2.2.1 How egg donation is currently organized   
Young healthy women are asked to give their oocytes in return for some form of 
compensation, usually monetary. In most countries egg donors are first recruited. 
Synchronized cycles between recipient and donors are organized, eggs are shared with 
several recipients (depending on the number collected), and excess eggs are attributed to the 
recipient in case of implantation failure, resulting in super numerous embryos which are 
frozen even if the number is low (Boyer et al., 2010). One or more freezing/thawing cycles 
are usually included. With oocyte vitrification there is a risk we will see the explosive 
development of a market for oocytes especially in poor countries where young women have 
few opportunities for work and the payment is comparatively high (as with organ 
donation). We are facing a cross-border organization for egg donation where physicians in 
foreign countries compete to provide the most medically secure environment for the 
recipient. It is no secret that demand will come from patients over 40 in wealthier countries 
who have no other possibility of delivering successfully.  
Over a period of ten years egg donation in Europe has increased more than three-fold, from 
4500 cycles in 1998 to 15,000 in 2007, with half the donations coming from Spain. Even if the 
results -- a 60 percent pregnancy rate per cycle -- are good, the development of egg 
donations is worrisome because most patients are older women beyond the age of child-
bearing. It is a flagrant example of the incursion of market practices in the medical 
profession. This problem is due to the nature of the demand but also to the growth of 
medical clinics run for financial profit. Biologists working in these clinics must reach goals 
set by financial directors. Health institutions today are guided more by financial 
considerations than medical. Today we see franchising of IVF units used as a tool to expand 
business. The unregulated European market has produced a situation which parallels the 
market worldwide, where certain practices migrate to countries with lower costs and/or 
looser regulation. Some centres propose an "all-in-one" stay that includes air tickets, hotel 
and on-site facilities. The world has seen a similar development in the fields of surrogacy, 
dentistry and cosmetic surgery. 
2.2.2 How egg donation can be organized in a near future  
The availability of unpaid oocytes is probably part of the solution. The possibility and 
quality of egg banking were assessed in a study by A. Cobo from IVI, presented at the 
ESHRE meeting in 2010 and published under the title, "A randomized, prospective, 
controlled-clinical trial to test the efficacy of oocyte banking in oocyte donation  
programs" (Cobo et al., 2010). This work, which demonstrates that ICSI using vitrified eggs 
produces the same results as with fresh recovered ones, marks a turning point in egg 
donation. 
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Oocyte vitrification makes in easier for each country to regulate its activity to fit the needs of 
its own population. Donations can be organized on a national scale, supervised by the 
health authorities of each country. Oocyte vitrification also will diversify the origin of 
donations. Oocytes from donors will be available but also from women who have 
undergone IVF treatment resulting in a successful pregnancy but who still have oocytes 
stored in the clinic where ICSI was performed and extra-numerary oocytes cryopreserved. 
Some of these women may agree to donate their “unused” oocytes to a national bank, and a 
national network can be organized. After some years of vitrified oocyte use, the number of 
eggs available for donation will tend to self-sufficiency.  
2.3 Preventing loss of fertility 
Female fertility is naturally limited to the years between puberty and menopause. The 15 
best years are from the ages of 20 to 35. By the age of thirty, half of the oocytes available 
after birth have vanished (Gougeon et al., 1994, Faddy et al., 1995, Scheffer et al., 1999 
Alviggi et al., 2009).  
Oocyte freezing offers new possibilities for women who face loss of fertility either through 
familial risk or during medical treatment of serious pathologies (oncological diseases, etc.)  
2.3.1 Identified familial or personal risk  
When genetically-induced ovarian failure appears, it is often too late to preserve fertility 
because of the lack of oocytes, even if the woman is still young. However, the early 
prevention of fertility loss in patients with a known family history of premature infertility is 
possible. In some families, premature ovarian failure was identified in a woman’s relatives 
who carried genetic mutations that interfere with the fertility timeline. In some cases a 
woman, although fertile at the age of 20, discovers she has lost her fertility ten years later, 
like her mother or aunt. In other cases, the discovery of the rearrangement of sex 
chromosomes may predict a shortened fertile life. It has been reported that carriers of 
Turner’s syndrome can have their own oocytes in the early stages of the reproductive period 
(Haseltine et al., 1984).  
By performing ovarian stimulation and collecting some oocytes while a woman still has antral 
follicles, it is possible to perform IVF later when she decides to use her eggs. Collecting them 
early in a woman’s life can protect her from programmed premature menopause. With a few 
good oocytes, she maintains the possibility of bearing children later on. 
2.3.2 Consequences of sterilizing treatments 
Treatment for chronic or ontological diseases can affect a woman’s fertility, partially or 
definitively. In almost all such cases, survival and cure rates are high and the woman is 
young enough to conceive after recovery. In the past ten years, the medical focus for such 
patients has been the cryopreservation of cortical fragments of the ovaries, and the 
programming of a graft for a hormonal ovarian cycle recovery. In rare cases an attempted 
pregnancy has been suggested to restore fertility. Some births have been reported but 
remain low due to the difficulties of the surgical procedure (Roux et al., 2010). By vitrifying 
oocytes in some women who are able to undergo ovarian stimulation before treatment, 
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preservation of fertility will be more efficient (Porcu et al., 2008, Noyes et al., 2011). The new 
method provides a better alternative for women facing loss of sterility through treatment of 
certain diseases. 
2.3.3 Embryo freezing has new rival for preserving female fertility 
However, the most interesting prospect offered by oocyte vitrification is societal -- it is 
now possible to avoid cryopreservation of the embryo. Many prominent bodies have 
argued that cryopreservation of the embryo is safe and efficient, thus legitimizing its use 
for the preservation of woman’s fertility. This has been the position of the American 
Society for Reproductive Medicine (Practice Committee of ASRM 2008), the French 
College of Gynaecology and Obstetrics (Bringer et al., 2010) and probably that of many 
other countries. We regard this as a true mistake. Take the case of the Evans couple which 
was brought before the European Court of Human Rights (European Court of Human 
Rights 2006). In 2000 the Evans were faced with a difficult situation. Mrs Evans was 
diagnosed with an ovarian tumour. They were advised by medical staff to proceed with 
IFV as a couple, and as a result six embryos were obtained and cryopreserved. The couple 
later divorced and Mrs Evans was denied use of the embryos. Mr Evans would not 
consent to an embryo transfer. She took her case to the European Court of Human Rights 
which ruled in her former husband’s favour. The position of the European Court was that 
his right to withdraw consent was stronger than her right to use the embryos without his 
consent. For Mrs Evans it was a double condemnation -- her ability to have her own 
children was taken away, first through illness and again by the courts. With oocyte 
vitrification such an outcome could have been avoided, because she would have been sole 
owner of her eggs.  
It should also be noted that the current debate over the future of unused embryos could 
become irrelevant. Should they be destroyed? Given to another couple? Is it legitimate to 
refuse embryo transfer post-mortem? Or to accept post-mortem transfer but within certain 
time limits? And if so, how long after death? And how many transfers should be allowed? 
As long as the preservation of embryos is the preferred method, these issues will continue to 
plague societies. 
A few years ago in the French city of Toulouse a woman was refused an embryo transfer 
because her husband (the "father") was no longer alive. The court ruled that her embryos be 
proposed for "very early adoption" because of a 2004 law in France prohibiting destruction 
of human embryos. 
Today, we are no longer being forced to choose between the right to motherhood and the 
right not to become father. Women are now able to preserve their gametes. Oocyte 
vitrification will resolve a number of ethical issues surrounding the use of the human 
embryo, without creating new dilemmas. We must be prepared at some point to admit our 
error in promoting embryo freezing as a means of preserving fertility and recognize that this 
is not a minor issue. 
As underlined by Cobo, the American Society for Reproductive Medicine concludes, 
‘‘Oocyte cryopreservation presently should be considered an experimental technique only to 
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be performed under investigational protocol under the auspices of an Institutional Review 
Board.” The French College of Gynaecologists et Obstetricians reaches a similar conclusion. 
All such professional organizations have a duty to rectify their position, once proof of error 
has been reasonably established.  
3. Conclusion 
The time has come to reorganize our daily practice, integrating oocyte vitrification into 
our routines. The efficiency of the combined techniques of ICSI and oocyte vitrification 
has transformed our environment, necessitating the creation of cryobiology units in all 
our labs where that has not already been done. We may rejoice in this recognition of our 
speciality in the field of medicine. We must continue to form a new generation of 
specialists, in a professional world very different from what we once knew. In over 30 
years of practice we have been witness every ten years to major changes in the field. We 
must share our experience with the new generation, while hoping fervently they will have 
the freedom to follow. In today's often oppressive regulatory environment, practitioners 
are caught up in concerns over quality control, their CE mark and ISO15189 accreditation. 
We will lose our souls this way. Regulatory pressures have led not only to modifications 
of all our procedures, they have transformed the structural functioning of our units. As 
biologists we must reassert our control in the lab. We cannot delegate the most critical 
aspects of our procedures to technicians who lack the understanding to take medical 
decisions. 
The advent of oocyte vitrification, like the introduction of ICSI before, poses a real challenge. 
This challenge will be met with success by all those who have chosen to dedicate their lives 
to reproductive biology. We are on the threshold of a cryobiological revolution. We can 
preserve oocytes today. In the future we will be able to preserve entire organs. We are 
fortunate to be working in this amazing field; may we remain passionate about our true 
mission -- to help patients. The introduction of oocyte vitrification represents a major step in 
the field of reproductive biology. It will transform our procedures, curtail the 
cryopreservation of embryos and resolve many issues surrounding the status of the human 
embryo. The advances are medical but they will have broad political, social and legal impact 
as well. 
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